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Abstract 
Background: Abacavir and rilpivirine are alternative antiretroviral drugs for treatment‑naïve HIV‑infected patients. 
However, both drugs are only recommended for the patients who have pre‑treatment HIV RNA <100,000 copies/mL. 
In resource‑limited settings, pre‑treatment HIV RNA is not routinely performed and not widely available. The aims of 
this study are to determine factors associated with pre‑treatment HIV RNA <100,000 copies/mL and to construct a 
model to predict this outcome.
Methods: HIV‑infected adults enrolled in the TREAT Asia HIV Observational Database were eligible if they had an HIV 
RNA measurement documented at the time of ART initiation. The dataset was randomly split into a derivation data set 
(75% of patients) and a validation data set (25%). Factors associated with pre‑treatment HIV RNA <100,000 copies/mL 
were evaluated by logistic regression adjusted for study site. A prediction model and prediction scores were created.
Results: A total of 2592 patients were enrolled for the analysis. Median [interquartile range (IQR)] age was 35.8 (29.9–
42.5) years; CD4 count was 147 (50–248) cells/mm3; and pre‑treatment HIV RNA was 100,000 (34,045–301,075) copies/
mL. Factors associated with pre‑treatment HIV RNA <100,000 copies/mL were age <30 years [OR 1.40 vs. 41–50 years; 
95% confidence interval (CI) 1.10–1.80, p = 0.01], body mass index >30 kg/m2 (OR 2.4 vs. <18.5 kg/m2; 95% CI 1.1–5.1, 
p = 0.02), anemia (OR 1.70; 95% CI 1.40–2.10, p < 0.01), CD4 count >350 cells/mm3 (OR 3.9 vs. <100 cells/mm3; 95% 
CI 2.0–4.1, p < 0.01), total lymphocyte count >2000 cells/mm3 (OR 1.7 vs. <1000 cells/mm3; 95% CI 1.3–2.3, p < 0.01), 
and no prior AIDS‑defining illness (OR 1.8; 95% CI 1.5–2.3, p < 0.01). Receiver‑operator characteristic (ROC) analysis 
yielded area under the curve of 0.70 (95% CI 0.67–0.72) among derivation patients and 0.69 (95% CI 0.65–0.74) among 
validation patients. A cut off score >25 yielded the sensitivity of 46.7%, specificity of 79.1%, positive predictive value 
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Background
Antiretroviral therapy (ART) for the treatment of human 
immunodeficiency virus (HIV) infection has dramatically 
reduced HIV-associated morbidity and mortality and has 
transformed HIV infection into a manageable chronic 
condition [1, 2]. Furthermore, early ART is highly effec-
tive in preventing HIV transmission to sexual partners 
[3]. More than 25 antiretroviral drugs (ARV) in 6 classes 
are approved for treatment of HIV infection [4]. Selec-
tion of an ARV regimen should be individualized on the 
basis of efficacy, adverse effects, pill burden, dosing fre-
quency, drug–drug interactions, comorbid conditions, 
and cost [4, 5].
The initial ARV regimen for a treatment-naïve HIV-
infected patient generally consists of 2 nucleoside/nucle-
otide reverse transcriptase inhibitors, usually abacavir 
(ABC) plus lamivudine (3TC) or tenofovir disoproxil 
fumarate plus emtricitabine (TDF/FTC), plus a drug 
from 1 of 3 drug classes: an integrase strand transfer 
inhibitor, a non-nucleoside reverse transcriptase inhibi-
tor (NNRTIs), or a boosted protease inhibitor [4, 5]. ABC 
is usually preferred over TDF for individuals with chronic 
kidney disease and/or those at risk of osteoporosis and 
fractures [4, 5]. However, ABC is recommended for 
patients who are HLA-B*5701 allele negative and have a 
pre-treatment HIV RNA <100,000 copies/mL [6], except 
when used with dolutegravir (DTG) and 3TC in the same 
regimen [4, 5].
Rilpivirine (RPV) is a recently approved NNRTI avail-
able at relatively low cost in Thailand (7 USD per month) 
and other countries. The advantages of RPV are once-
daily dosing and very small pill size. In addition, RPV is 
associated with fewer treatment discontinuations for 
central nervous system adverse effects, fewer lipid effects, 
and fewer rashes when compared with efavirenz (EFV) 
[7, 8]. Nevertheless, RPV has a higher rate of virologi-
cal failure when compared to EFV, especially in the first 
48 weeks of treatment [7]. RPV is thus recommended as 
an alternative option for treatment naïve HIV-infected 
patients with a pre-treatment HIV RNA <100,000 copies/
mL and CD4 count >200 cells/mm3 [4, 5].
Testing of HIV RNA levels is recommended during 
initial patient visits by treatment guidelines in devel-
oped countries [4, 5]. In resource-limited settings, pre-
treatment HIV RNA is not routinely performed and not 
widely available [9, 10]. This limits the use of ABC and 
RPV as a component of the first-line ARV regimen. If a 
clinical prediction tool based on routinely collected data 
could accurately predict whether pre-treatment HIV 
RNA was <100,000  copies/mL, this could be applied 
into clinical practice. The aims of this study are to deter-
mine factors associated with pre-treatment HIV RNA 
<100,000  copies/mL and to construct prediction tools 
that predict a pre-treatment HIV RNA <100,000 copies/
mL. This prediction tool might support the use of ABC 
and RPV as part of first-line regimens for selected treat-
ment-naïve HIV-infected individuals in resource-limited 
settings with limited access to HIV RNA testing.
Patients and methods
Our study population consisted of HIV-infected patients 
enrolled in the TREAT (Therapeutics Research, Educa-
tion, and AIDS Training) Asia HIV Observational Data-
base (TAHOD). The characteristics of this cohort have 
been described previously. Briefly, TAHOD is a prospec-
tive multi-center, observational study of patients with 
HIV and aims to assess HIV disease natural history in 
treated and untreated patients in the Asia and Pacific 
region [11]. We included patients enrolled in the cohort 
from 23 clinical sites throughout 13 countries in the Asia 
Pacific region since September 2003. The date of data 
censoring for the analysis of this study was 31 March 
2015.
HIV-infected adults enrolled in TAHOD were eligi-
ble if they had an HIV RNA measurement documented 
at or around the time of ART initiation (pre-treatment 
HIV RNA). The window period of pre-treatment HIV 
RNA measurement was between 3 months prior to 1 day 
after the date of starting ART. ART was defined as a regi-
men containing ≥3 ARVs. Those exposed to mono or 
dual therapy prior to starting combination ART were 
excluded. Baseline was defined as the date of ART ini-
tiation. At baseline, co-variables included age, sex, HIV 
exposure, hepatitis B and C serology (ever positive), 
time since diagnosis of HIV infection, HIV subtype, and 
AIDS diagnosis prior to baseline. The window period of 
the following co-variables was between 3  months prior 
to 3 months after the date of ART initiation; body mass 
index (BMI), anemia (hemoglobin <13  g/dL for men, 
<12  g/dL for women), total lymphocyte count, CD4 
of 67.7%, and negative predictive value of 61.2% for prediction of pre‑treatment HIV RNA <100,000 copies/mL among 
derivation patients.
Conclusion: A model prediction for pre‑treatment HIV RNA <100,000 copies/mL produced an area under the ROC 
curve of 0.70. A larger sample size for prediction model development as well as for model validation is warranted.
Keywords: Abacavir, HIV RNA, Model, Prediction, Rilpivirine
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count, CD8 count, CD4:CD8 ratio, and syphilis serology 
[Rapid plasma reagin (RPR), Venereal Disease Research 
Laboratory (VDRL) or Treponema pallidum particle 
agglutination assay (TPHA)].
Statistical analysis
The dataset was randomly split into a derivation data set 
(containing data from 75% of all eligible patients) and vali-
dation data set (containing data from 25% of all eligible 
patients) using the PROC SURVEYSELECT command in 
SAS version 9.4 (SAS Institute Inc., Cary, North Carolina, 
USA). The study endpoint was pre-treatment HIV RNA 
<100,000  copies/mL. Factors associated with this end-
point were evaluated by logistic regression adjusted for 
study site. Co-variables were considered for inclusion in 
the multivariate model if one or more categories exhib-
ited a p-value <0.1. They were retained in the multivariate 
model if one or more categories exhibited a p-value <0.05. 
Missing categories, where present, were included in all 
models but odds ratios (OR) were not shown.
Prediction scores were created by multiplying the OR 
for each multivariate co-variable category by 10 and sub-
tracting 1 [12]. Scores were rounded to the nearest 0.5 
points. Some categories among the variables including in 
the multivariate model gave similar OR and were there-
fore collapsed together for the prediction tool.
The discrimination was evaluated using the area under 
the receiver-operator characteristic (AUROC) curve 
[13]. We used data of patients that had data available on 
all variables including in the prediction model. The opti-
mum cut-off point for the score was evaluated by sensi-
tivity, specificity, positive predictive value, and negative 
predictive value. Stata version 14.1 (StataCorp, College 
Station, Texas, USA) was used for all statistical analysis.
Results
A total of 2592 patients were included in our derivation 
analysis. Median [interquartile range (IQR)] age was 35.8 
(29.9–42.5) years, 56.2% had heterosexual HIV exposure, 
median (IQR) BMI was 21.1 (19.0–23.4)  kg/m2, median 
duration of HIV diagnosis was 4.3 (1.4–29.2)  months, 
and 34.5% had prior AIDS-defining illness. Median CD4 
count was 147 (50–248) cells/mm3 and median pre-treat-
ment HIV RNA was 100,000 (34,045–301,075)  copies/
mL. For other laboratory investigations, 49.3% had ane-
mia, 10.8% had positive HBsAg, 8.3% had positive anti-
HCV, 19.6% had positive syphilis serology, and 75.1% had 
HIV infection with CRF01_AE subtype. Baseline charac-
teristics of the patients are shown in Table 1.
Factors that statistically significantly associated with 
pre-treatment HIV RNA <100,000 copies/mL in the 
derivation patients by multivariate logistic regression, 
Table 1 Baseline characteristics of  2592 HIV-infected 
patients
IQR interquartile range
a  Values are n (% total) unless otherwise specified
Baseline characteristics Valuea
Median (IQR) age, years 35.8 (29.9–42.5)
Male 1883 (72.6)
HIV exposure
 Heterosexual 1456 (56.2)
 Homosexual 778 (30.0)
 Intravenous drug use 93 (3.6)
 Other 265 (10.2)
Median (IQR) body mass index, kg/m2 21.1 (19.0–23.4)
  Missing 683 (26.4)
Anemia
 No, n (% tested) 1208 (50.7)
 Yes, n (% tested) 1176 (49.3)
 Unknown 208 (8.0)
Hepatitis B surface antigen
 Negative, n (% tested) 1925 (89.2)
 Positive, n (% tested) 232 (10.8)
 Unknown 435 (16.8)
Hepatitis C antibody
 Negative, n (% tested) 1844 (91.7)
 Positive, n (% tested) 168 (8.3)
 Unknown 580 (22.4)
Syphilis serology
 Negative, n (% tested) 825 (80.4)
 Positive, n (% tested) 201 (19.6)
 Unknown 1566 (60.4)
Median (IQR) duration of HIV diagnosis, 
months
4.3 (1.4–29.2)
  Missing 29 (1.1)
HIV subtype
 CRF01_AE, n (% tested) 796 (75.1)
 B, n (% tested) 173 (16.3)
 Other, n (% tested) 91 (8.6)
 Unknown 1532 (59.1)
Median (IQR) HIV RNA, copies/mL 100,000 (34,045–301,075)
Median (IQR) CD4 count, cells/mm3 147 (50–248)
  Missing 106 (4.1)
Median (IQR) CD8 count, cells/mm3 753 (485–1103)
  Missing 1268 (48.9)
Median (IQR) CD4:CD8 ratio 0.19 (0.09–0.32)
  Missing 1268 (48.9)
Median (IQR) total lymphocyte count, cells/
mm3
1472 (1000–2005)
  Missing 286 (11.0)
Prior AIDS illness
 No 1698 (65.5)
 Yes 894 (34.5)
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were age <30 years [OR 1.40 vs. 41–50  years; 95% con-
fidence interval (CI) 1.10–1.80, p  =  0.01], body mass 
index >30 kg/m2 (OR 2.4 vs. <18.5 kg/m2; 95% CI 1.1–5.1, 
p = 0.02), anemia (OR 1.70; 95% CI 1.40–2.10, p < 0.01], 
CD4 count >350  cells/mm3 (OR 3.9 vs. <100  cells/
mm3; 95% CI 2.0–4.1, p < 0.01), total lymphocyte count 
>2000  cells/mm3 (OR 1.7 vs. <1000 cells/mm3; 95% CI 
1.3–2.3, p < 0.01), and no prior AIDS-defining illness (OR 
1.8; 95% CI 1.5–2.3, p < 0.01) (Table 2).
Clinical prediction tool scores for pre-treatment HIV 
RNA <100,000 copies/mL are shown in Table  3. Scores 
were +3.5 for age <30  years, +2.5 for BMI of 18.5–
29.9 kg/m2 or +14.5 for BMI of >30 kg/m2, +7.0 for non-
anemia, +17.0 for CD4 count >200 cells/mm3 or +5.5 for 
100–199 cells/mm3, and +8.5 for no prior AIDS-defining 
illness. The possible maximum score was 50.5.
AUROC analysis was 0.70 (95% CI 0.67–0.72) among 
the derivation patients (Fig.  1) and 0.69 (95% CI 0.65–
0.74) among validation patients.
A cut off total score >25 yielded sensitivity of 46.7 and 
47.4%, specificity of 79.1 and 77.1%, positive predictive 
value of 67.7 and 64.2%, and negative predictive value 
of 61.2 and 63.0% for pre-treatment HIV RNA <100,000 
copies/mL among the derivation patients and validation 
patients, respectively (Tables  4, 5). In contrast a cut off 
score >5 yielded the highest sensitivity of 91.1 and 91.9% 
and lowest specificity of 24.8 and 24.1% among derivation 
patients and validation patients, respectively (Tables  4, 
5). We also conducted a sensitivity analysis using other 
prediction models, e.g. using total lymphocyte count 
instead of CD4 count and restriction analysis only among 
patients with CD4 count >200 cells/mm3, however these 
models did not perform better.
Discussion
Plasma HIV RNA is one laboratory test used to stage 
HIV disease and to assist in the selection of ARV drug 
regimens [4, 5]. If treatment-naïve HIV-infected patients 
have a pre-treatment HIV RNA >100,000 copies/mL, the 
following regimens are not recommended; ABC/3TC 
with EFV or atazanavir/ritonavir (ATV/r) or raltegravir 
(RAL), RPV-based regimens, and darunavir/r (DRV/r) 
plus RAL [4, 5]. The main reason is being the higher rates 
of virologic failure observed in patients who received 
these particular drugs [7]. In addition, patients with pre-
treatment HIV RNA >100,000 copies/mL or CD4 count 
<200  cells/μL are a subset of patients who may experi-
ence suboptimal virologic suppression if the regimen 
consists of ABC or PRV [5].
To our knowledge, this is the first study on predic-
tion tool of pre-treatment HIV RNA <100,000  copies/
mL in treatment-naïve HIV-infected patients that aims 
to facilitate the use of ABC and RPV as one of ARV in 
the first-line ART in resource-limited settings. We 
found some clinical and laboratory factors statistically 
significantly associated with pre-treatment HIV RNA 
<100,000  copies/mL. Our prediction tool of pre-treat-
ment HIV RNA <100,000 copies/mL performed AUROC 
curve of 0.70. A cut off score >25 yielded the highest 
specificity of 79.0% for predicting pre-treatment HIV 
RNA <100,000 copies/mL.
Few studies focus on the association between HIV 
RNA levels and HIV-related outcomes. The results from 
some previous studies showed that HIV RNA level is 
rarely directly associated with the type of opportunistic 
infection [14] or HIV disease progression [15]. One study 
demonstrated a significant correlation between HIV 
RNA level and wasting syndrome in naïve HIV-infected 
patients, with HIV RNA levels in patients with wasting 
syndrome, significantly higher than those without the 
condition [16].
We also found six independent factors associated 
with pre-treatment HIV RNA <100,000  copies/mL: 
age, BMI, anemia, CD4 count, total lymphocyte count, 
and prior AIDS-defining illness. For example, patients 
with age <30 years had higher odds of 1.4 of having pre-
treatment HIV RNA <100,000  copies/mL compared to 
patients 41–50  years old. Furthermore, patients with 
baseline CD4 count 100–199 cells/mm3 had higher odds 
of 1.6 of having pre-treatment HIV RNA <100,000 cop-
ies/mL compared to patients with baseline CD4 count 
<100 cells/mm3. These factors might be easily applied in 
the assessment of patients in resource-limited settings 
because they are patients’ clinical characteristics and 
routine baseline laboratory investigations.
The AUROC curve is a single index for measuring the 
performance a test and can be used to estimate the dis-
criminating power of a test. The AUROC of a ‘perfect’ 
test would be 1.00, that of a useless test, 0.50 [13, 17]. 
The AUROC for the pre-treatment HIV RNA model 
applied to the derivation population was 0.70. The 
AUROC curve when the model was applied to the vali-
dation population was 0.69, indicating some loss of dis-
criminating power when applied to the new population. 
The score >5 showed the highest sensitivity but low-
est specificity. With prediction of pre-treatment HIV 
RNA <100,000  copies/mL, higher specificity is required 
to minimize false positive results. Using a score >25 for 
prediction of pre-treatment HIV RNA yielded specificity 
approximately 80% and positive predictive value almost 
70% and might be more appropriate. Additional data var-
iables and/or an increased number of the patients might 
be needed to improve this prediction model and enhance 
its performance.
This study had some limitations. First, some patients 
must be excluded from the regression analysis and from 
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Table 2 Factors associated pre-treatment HIV RNA <100,000 copies/mL in derivation population
Factors Number  
of patients
Patients (% total) with  
HIV RNA <100,000 copies/mL
Univariate OR  
(95% CI)
p-value Multivariate OR  
(95% CI)
p- value
Years of  ageb
 ≤30 656 360 (54.9) 1.6 (1.2–2.0) <0.01 1.4 (1.1–1.8) 0.01
 31–40 1057 514 (48.6) 1.2 (0.9–1.4) 0.15 1.1 (0.9–1.4) 0.40
 41–50 600 273 (45.5) 1.0 1.0
 >50 279 131 (47.0) 1.0 (0.8–1.4) 0.85 1.0 (0.7–1.4) 0.96
Sexb
 Male 1883 908 (48.2) 1.0
 Female 709 370 (52.2) 1.2 (1.0–1.5) 0.02
HIV exposure
 Heterosexual 1456 688 (47.3) 1.0
 Homosexual 778 422 (54.2) 1.3 (1.0–1.6) 0.03
 Intravenous drug use 93 41 (44.1) 0.9 (0.6–1.4) 0.54
 Other 265 127 (47.9) 0.9 (0.7–1.3) 0.70
Body mass index (kg/m2)b
 <18.5 366 134 (36.6) 1.0 1.0
 18.5–24.9 1289 648 (50.3) 1.7 (1.3–2.2) <0.01 1.3 (1.0–1.7) 0.07
 25.0–29.9 213 112 (52.6) 1.8 (1.3–2.6) <0.01 1.2 (0.8–1.7) 0.47
 ≥30.0 41 29 (70.7) 4.1 (2.0–8.4) <0.01 2.5 (1.2–5.2) 0.02
 Unknown 683 355 (52.0) – –
Anemiab
 No 1208 741 (61.3) 2.7 (2.3–3.3) <0.01 1.7 (1.4–2.1) <0.01
 Yes 1176 442 (37.6) 1.0 1.0
 Unknown 208 95 (45.7) – –
Hepatitis C antibody
 Negative 1844 916 (49.7) 1.0
 Positive 168 73 (43.5) 0.8 (0.6–1.1) 0.15
 Unknown 580 289 (49.8) –
Month since HIV diagnosis
 <6 1384 614 (44.4) 1.0
 6–18 338 189 (55.9) 1.6 (1.3–2.1) <0.01
 >18 841 461 (54.8) 1.5 (1.3–1.8) <0.01
 Unknown 29 14 (48.3) –
CD4 count (cells/mm3)b
 ≥350 219 147 (67.1) 4.8 (3.4–6.7) <0.01 2.9 (2.0–4.1) <0.01
 200–349 694 456 (65.7) 4.2 (3.4–5.3) <0.01 2.7 (2.1–3.4) <0.01
 100–199 617 308 (49.9) 2.1 (1.7–2.6) <0.01 1.6 (1.2–2.0) <0.01
 <100 956 318 (33.3) 1.0 1.0
 Unknown 106 49 (46.2) – –
Total lymphocyte count (cells/mm3)a
 ≥2000 593 325 (54.8) 2.9 (2.2–3.7) <0.01 1.7 (1.3–2.3)
 1500–1999 529 303 (57.3) 2.9 (2.3–3.7) <0.01 1.8 (1.4–2.4)
 1000–1499 627 331 (52.8) 2.3 (1.8–2.9) <0.01 1.6 (1.3–2.1) <0.01
 <1000 557 180 (32.3) 1.0 1.0
 Unknown 286 139 (48.6) – –
Prior AIDS‑defining  illnessa
 None known 1698 987 (58.1) 3.0 (2.5–3.6) <0.01 1.8 (1.5–2.3) <0.01
 Yes 894 291 (32.6) 1.0 1.0
OR odds ratio, CI confidence interval
a  Multivariate result shows effect size when replacing CD4 count
b  Included in the final model
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the prediction tool due to missing data. Second, the per-
formance of the model described by the AUROC of 0.70 
might be associated with the small sample size of the 
study population among derivation and validation group.
In conclusion, in  situations where HIV RNA cannot 
be obtained prior to ART initiation due to high costs or 
limited availability, certain risk factors and models for 
predicting pre-treatment HIV RNA <100,000 copies/mL 
might be useful to predict pre-treatment HIV RNA and 
afford opportunities for ABC and RPV initiation among 
naïve HIV-infected patients. A larger sample size with 
greater data variety would be warranted for prediction 
model construction as well as for model validation. Pre-
treatment HIV RNA should be performed before ABC 
and RPV initiation if it is available and affordable.
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Table 3 Clinical prediction tool scores for  each variable 
for pre-treatment HIV RNA <100,000 copies/mL
Variables Score
Age ≤30 years +3.5
Age >30 years 0
Body mass index <18.5 kg/m2 0
Body mass index 18.5–29.9 kg/m2 +2.5
Body mass index ≥30 kg/m2 +14.5
Anemic 0
Non‑anemic +7.0
CD4 count ≥200 cells/mm3 +17.0
CD4 count 100–199 cells/mm3 +5.5
CD4 count <100 cells/mm3 0
No prior AIDS‑defining illness +8.5
Prior AIDS‑defining illness 0
Maximum score 50.5
Fig. 1 Receiver‑operator characteristic curve for predicting pre‑
treatment HIV RNA <100,000 copies/mL among derivation patients 
with data on all included variables (n = 1757)
Table 4 Sensitivities, specificities, positive predictive values, and  negative predictive values of  clinical prediction tool 
for pre-treatment HIV RNA <100,000 copies/mL among derivation patients with data on all included variables (n = 1757)
CPT clinical prediction tool, PPV positive predictive value, NPV negative predictive value
CPT score N (%) N (%) tests avoided Sensitivity (%) Specificity (%) PPV (%) NPV (%)
>25.0 586 (37.7) 1171 (75.3) 46.7 79.1 67.7 61.2
>20.0 764 (49.1) 993 (63.8) 58.0 70.2 64.7 64.0
>15.0 1018 (65.4) 739 (47.5) 72.3 55.5 60.4 68.1
>10.0 1239 (79.6) 518 (33.3) 81.3 39.6 55.9 69.3
>5.0 1456 (93.6) 301 (19.3) 91.1 24.8 53.2 74.8
Table 5 Sensitivities, specificities, positive predictive 
values, and  negative predictive values of  clinical predic-
tion tool for  pre-treatment HIV RNA <100,000 copies/mL 
among  validation patients with  data on  all included vari-
ables (n = 587)














>25.0 201 (39.5) 386 (75.8) 47.4 77.1 64.2 63.0
>20.0 264 (51.9) 323 (63.5) 61.0 68.9 62.9 67.2
>15.0 355 (69.7) 232 (45.6) 75.4 52.4 57.7 71.1
>10.0 421 (82.7) 166 (32.6) 84.6 39.4 54.6 74.7
>5.0 489 (96.1) 98 (19.3) 91.9 24.1 51.1 77.6
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